LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

LLY

1,125.18

+4.16%↑

JNJ

228.23

+2.11%↑

ABBV

224.88

+3.55%↑

UNH

396.79

+4.98%↑

MRK

120.25

+4.69%↑

Inicio・Lista de Acciones・Krystal Biotech Inc

Krystal Biotech Inc

Cerrado

SectorSanidad

306.38 1.99

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

298.35

Máximo

311.94

Métricas clave
By Trading Economics
Ingresos	4.5M 56M
Ventas	9.3M 116M
P/B Media del Sector	39.046 49.888
BPA	1.83
Margen de beneficios	48.069
Empleados	295
EBITDA	16M 55M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+6.69% upside

Dividendos
By Dow Jones
Próximas Ganancias	3 ago 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	581M 8.6B
Apertura anterior	304.39
Cierre anterior	306.38

Noticias sobre sentimiento de mercado

By Acuity

38%

62%

110 / 344 Clasificación en Healthcare

Krystal Biotech Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

4 jun 2026, 21:51 UTC

Principales Movimientos del Mercado

Merlin Shares Rally After Defense Department's Design Review Wraps

4 jun 2026, 23:46 UTC

Charlas de Mercado

U.S. Jobs Data May Offer Bullish Catalyst for Dollar Vs. Yen -- Market Talk

4 jun 2026, 23:44 UTC

Charlas de Mercado

Nikkei May Decline Amid Middle East Uncertainty -- Market Talk

4 jun 2026, 23:42 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia: Court to Decide on Rio Tinto Compulsory Acquisition Request

4 jun 2026, 23:41 UTC

Adquisiciones, fusiones, absorciones

Energy Resources of Australia to Enter Trading Halt

4 jun 2026, 23:34 UTC

Charlas de Mercado

Oil Edges Lower Amid Mixed Middle East Developments -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Mercury NZ Loses Bull Despite Sector Earnings Powering Up -- Market Talk

4 jun 2026, 23:31 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

4 jun 2026, 23:08 UTC

Charlas de Mercado

Narrowing Rate Differentials Make Australian Dollar Less Attractive Versus USD -- Market Talk

4 jun 2026, 22:41 UTC

Charlas de Mercado

Australia Shares Set to Rise at the Open -- Market Talk

4 jun 2026, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 20:44 UTC

Adquisiciones, fusiones, absorciones

RTX Stock Rises After Catching an Upgrade. Why This Analyst Is Bullish. -- Barrons.com

4 jun 2026, 20:16 UTC

Charlas de Mercado

Mexican Demand Indicators Show Signs of Life -- Market Talk

4 jun 2026, 20:15 UTC

Adquisiciones, fusiones, absorciones

Gilead Sciences And Lakefront Complete Acquisition Of Ouro Medicines To Further Expand Inflammation Pipeline >GILD

4 jun 2026, 19:46 UTC

Charlas de Mercado

Treasury Yields Decline Ahead of U.S. Payrolls -- Market Talk

4 jun 2026, 19:38 UTC

Charlas de Mercado

Oil Futures Retreat After 3-Session Winning Streak -- Market Talk

4 jun 2026, 19:30 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Weather, Storage Data -- Market Talk

4 jun 2026, 18:47 UTC

Adquisiciones, fusiones, absorciones

Google Stock Attracts Cathie Wood's ARK and Berkshire Hathaway. That's Rare. -- Barrons.com

4 jun 2026, 18:38 UTC

Ganancias

Money Quote: Tech Weakness in Context -- WSJ

4 jun 2026, 18:24 UTC

Ganancias

Quantinuum, Broadcom, UnitedHealth, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 17:09 UTC

Charlas de Mercado

Retest of $55k Seen Possible for Bitcoin -- Market Talk

4 jun 2026, 16:58 UTC

Ganancias

Broadcom, UnitedHealth, Blackstone, Ciena, and More Stocks That Explain Today's Market -- Barrons.com

4 jun 2026, 16:46 UTC

Charlas de Mercado

Strategy BTC Sale Continues to Weigh on Prices -- Market Talk

4 jun 2026, 16:38 UTC

Ganancias

UnitedHealth Stock Rises. Why the Health Insurer Is Leading the Dow to Sharp Gains. -- Barrons.com

4 jun 2026, 16:20 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

4 jun 2026, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

4 jun 2026, 16:13 UTC

Charlas de Mercado

On Again, Off Again Deals Keep Oil Market on Edge -- Market Talk

4 jun 2026, 16:11 UTC

Charlas de Mercado

Copper Market Is Awaiting Key U.S. Tariff Decision -- Market Talk

4 jun 2026, 15:56 UTC

Charlas de Mercado

Copper Rises Amid Hormuz Disruptions, U.S. Stockpiling -- Market Talk

Comparación entre iguales

Cambio de precio

Krystal Biotech Inc previsión

Precio Objetivo

By TipRanks

6.69% repunte

Estimación a 12 Meses

Media 322 USD 6.69%

Máximo 378 USD

Mínimo 284 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Krystal Biotech Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

Comprar

Mantener

Vender

De acuerdo con 10 analistas que ofrecen calificaciones bursátiles a para Krystal Biotech Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

110 / 344 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.